News
IP Group: Research
IP Group portfolio company, Enterprise Therapeutics, has announced positive results from its Phase 2 trial for ETD001, its lead candidate for the treatment of cystic fibrosis. Enterprise is an on-balance-sheet direct investment in which IP Group was an early investor. CEO Greg Smith said, “this is a highly encouraging clinical milestone for Enterprise Therapeutics.’’
portfolio company, Enterprise Therapeutics, has announced positive results from its Phase 2 trial for ETD001, its lead candidate for the treatment of cystic fibrosis. Enterprise is an on-balance-sheet direct investment in which IP Group was an early investor. CEO Greg Smith said, “this is a highly encouraging clinical milestone for Enterprise Therapeutics.’’
